Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective
PaperCitations, authors & open-access status
Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 14 citations, 2019 year and bronze oa status.
14
Citations
2019
Year
bronze
OA Status